Compare Salesforce Inc (CRM) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Salesforce Inc trades at $228.97 (market cap $187.48B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.72 (market cap $58.74B). The key difference: Salesforce Inc is far larger — about 3.2× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| CRM | TAK | |
|---|---|---|
Market Cap | $187.48B | $58.74B |
Volume | 6,155,822 | 3,110,994 |
Sector | Technology | Health |
52-Week High | $266.23 | $19.05 |
52-Week Low | $150.12 | $13.23 |
Typical Hold Time | 89 Days | 1 Days |
Enterprise Value | $217.82B | $86.65B |
Dividend Yield | 0.77% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $229.13, up 2.04% today, showing strong fundamental performance with consistent earnings beats and robust revenue growth. The company maintains exceptional profitability with 77.28% gross margins and 21.99% net income margins. Technical indicators show a bearish trend with the stock trading near resistance at $230, while analyst consensus remains strongly bullish with a $271.91 price target representing 19% upside potential.
CRM presents a compelling investment opportunity with strong AI monetization growth and improving profitability, though facing near-term technical headwinds and software sector volatility. The stock trades at reasonable valuations (P/E 20.86) with solid cash flow generation, but investors should monitor competitive pressures and macroeconomic impacts on enterprise software spending.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
